BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 24395351)

  • 1. NDRG1 prognosticates the natural course of disease in WHO grade II glioma.
    Blaes J; Weiler M; Sahm F; Hentschel B; Osswald M; Czabanka M; Thomé CM; Schliesser MG; Pusch S; Luger S; Winkler F; Radbruch A; Jugold M; Simon M; Steinbach JP; Schackert G; Tatagiba M; Westphal M; Tonn JC; Gramatzki D; Pietsch T; Hartmann C; Glimm H; Vajkoczy P; von Deimling A; Platten M; Weller M; Wick W
    J Neurooncol; 2014 Mar; 117(1):25-32. PubMed ID: 24395351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
    Reuss DE; Sahm F; Schrimpf D; Wiestler B; Capper D; Koelsche C; Schweizer L; Korshunov A; Jones DT; Hovestadt V; Mittelbronn M; Schittenhelm J; Herold-Mende C; Unterberg A; Platten M; Weller M; Wick W; Pfister SM; von Deimling A
    Acta Neuropathol; 2015 Jan; 129(1):133-46. PubMed ID: 25427834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of histomolecular subgroups of adult anaplastic (WHO Grade III) gliomas: applying the 'integrated' diagnosis approach.
    Rajmohan KS; Sugur HS; Shwetha SD; Ramesh A; Thennarasu K; Pandey P; Arivazhagan A; Santosh V
    J Clin Pathol; 2016 Aug; 69(8):686-94. PubMed ID: 26743027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas.
    Dahlrot RH
    Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subtyping of gliomas of various WHO grades by the application of immunohistochemistry.
    Popova SN; Bergqvist M; Dimberg A; Edqvist PH; Ekman S; Hesselager G; Ponten F; Smits A; Sooman L; Alafuzoff I
    Histopathology; 2014 Feb; 64(3):365-79. PubMed ID: 24410805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical utility of fluorescence in situ hybridization (FISH) in morphologically ambiguous gliomas with hybrid oligodendroglial/astrocytic features.
    Fuller CE; Schmidt RE; Roth KA; Burger PC; Scheithauer BW; Banerjee R; Trinkaus K; Lytle R; Perry A
    J Neuropathol Exp Neurol; 2003 Nov; 62(11):1118-28. PubMed ID: 14656070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long noncoding RNA profiles reveal three molecular subtypes in glioma.
    Li R; Qian J; Wang YY; Zhang JX; You YP
    CNS Neurosci Ther; 2014 Apr; 20(4):339-43. PubMed ID: 24393335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enrichment of branched chain amino acid transaminase 1 correlates with multiple biological processes and contributes to poor survival of IDH1 wild-type gliomas.
    Yi L; Fan X; Li J; Yuan F; Zhao J; Nistér M; Yang X
    Aging (Albany NY); 2021 Jan; 13(3):3645-3660. PubMed ID: 33493139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
    Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C
    Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo Metabolic Profiles as Determined by
    Wenger KJ; Hattingen E; Franz K; Steinbach J; Bähr O; Pilatus U
    Clin Neuroradiol; 2019 Mar; 29(1):27-36. PubMed ID: 28983683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma.
    Cheng W; Li M; Jiang Y; Zhang C; Cai J; Wang K; Wu A
    J Neurosurg; 2016 Jul; 125(1):7-16. PubMed ID: 26544773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
    Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
    BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematically characterize the clinical and biological significances of 1p19q genes in 1p/19q non-codeletion glioma.
    Chai RC; Zhang KN; Chang YZ; Wu F; Liu YQ; Zhao Z; Wang KY; Chang YH; Jiang T; Wang YZ
    Carcinogenesis; 2019 Oct; 40(10):1229-1239. PubMed ID: 31157866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anaplastic glioma. Neuropathology, molecular diagnostics and current study concepts].
    Wick W; Weller M
    Nervenarzt; 2010 Aug; 81(8):928-30, 932-5. PubMed ID: 20635074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas.
    Etxaniz O; Carrato C; de Aguirre I; Queralt C; Muñoz A; Ramirez JL; Rosell R; Villà S; Diaz R; Estival A; Teixidor P; Indacochea A; Ahjal S; Vilà L; Balañá C
    J Neurooncol; 2017 Nov; 135(2):273-284. PubMed ID: 28884377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China.
    Li S; Yan C; Huang L; Qiu X; Wang Z; Jiang T
    Neuro Oncol; 2012 Jan; 14(1):109-16. PubMed ID: 22039037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas.
    Sabha N; Knobbe CB; Maganti M; Al Omar S; Bernstein M; Cairns R; Çako B; von Deimling A; Capper D; Mak TW; Kiehl TR; Carvalho P; Garrett E; Perry A; Zadeh G; Guha A; Sidney Croul
    Neuro Oncol; 2014 Jul; 16(7):914-23. PubMed ID: 24470545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extent of resection and molecular pathologic subtype are potent prognostic factors of adult WHO grade II glioma.
    Choi J; Kim SH; Ahn SS; Choi HJ; Yoon HI; Cho JH; Roh TH; Kang SG; Chang JH; Suh CO
    Sci Rep; 2020 Feb; 10(1):2086. PubMed ID: 32034238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy.
    Weiler M; Blaes J; Pusch S; Sahm F; Czabanka M; Luger S; Bunse L; Solecki G; Eichwald V; Jugold M; Hodecker S; Osswald M; Meisner C; Hielscher T; Rübmann P; Pfenning PN; Ronellenfitsch M; Kempf T; Schnölzer M; Abdollahi A; Lang F; Bendszus M; von Deimling A; Winkler F; Weller M; Vajkoczy P; Platten M; Wick W
    Proc Natl Acad Sci U S A; 2014 Jan; 111(1):409-14. PubMed ID: 24367102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Correlation between loss of heterozygosity on chromosome 1p and 19q and expression of MGMT, p53 and Ki-67 proteins in gliomas].
    Huang L; Jiang T; Yuan F; Li GL; Xu LX; Cui Y
    Zhonghua Zhong Liu Za Zhi; 2011 Oct; 33(10):752-8. PubMed ID: 22335907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.